

(including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Claims:

Please cancel claim 53.

Please replace pending claims 54-56, 58-61 and 65-68 with the following claims 35, 54-56, 58-61 and 65-68.

54. Complexes according to claim 35, characterised in that the nucleic acid codes for one or more cytokines.

C¹ 55. Complexes according to claim 35, characterised in that the nucleic acid codes for one or more tumor antigens or fragments thereof.

56. Complexes according to claim 35, characterised in that the nucleic acid is a suicide gene.

C² 58. Process for preparing complexes according to claim 35, characterised in that first DNA and PEI, optionally modified with a cellular ligand, are complexed by mixing solutions of the DNA and the PEI and then the hydrophilic polymer is bound to PEI.

59. Process according to claim 58, characterised in that the final DNA concentration is about 5 to 50 µg of DNA/ml.

C2 60. Process according to claim 59, characterised in that the final DNA concentration is about 10 to 40 µg of DNA/ml.

61. Process according to claim 59, characterised in that the complexing is carried out at a salt concentration below the concentration of salt in HBS (150 mM NaCl, 20 mM HEPES, pH 7.3).

65. A composition containing one or more complexes according to claim 35.

66. The composition according to claim 65, characterised in that it contains the complexes in a concentration of about 200 µg/ml to about 1 mg/ml, based on DNA.

C3 67. The composition according to claim 65, characterised in that the complexes contain DNA which codes for one or more cytokines.

68. The composition according to claim 65, characterised in that the complexes contain DNA which codes for one or more tumor antigens or fragments thereof, optionally combined with DNA which codes for one more cytokines.
